Roche declares their leukemia drug venetoclax receives FDA grant for breakthrough therapy designation

May 7, 2015 1:05 PM

27 0

The Food and Drug Administration of the United States have approved breakthrough therapy designation to a Swiss drug manufacturer, Roche Holding AG (RO.EB) for leukemia drug, venetoclax for accelerating the regulatory review process for the therapy.

Roche, the Basel-based company has announced on Thursday that the FDA has given the expedited review to venetoclax that is being tested for treating a type of chronic lymphocytic leukemia with a genetic abnormality that is called 17p deletion. Venetoclax has been developed by Roche partnering with A...

Read more

To category page